ArticleCureus2026
Solitary Parotid Metastasis as an Atypical Site of Recurrence in Lung Squamous Cell Carcinoma: A Diagnostic Difficulty.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung squamous cell carcinoma (LSCC) rarely metastasizes to the parotid gland, with only a handful of cases reported in the literature. Its clinical and pathological presentations closely mimic those of primary parotid squamous cell carcinoma (PSCC). Differentiating solitary metastasis from metachronous primary squamous cell carcinoma (SCC) in patients with a history of smoking and lung cancer presents a significant diagnostic challenge. A 55-year-old man with a history of heavy smoking presented with a solitary parotid mass two years after curative LSCC resection. Excisional biopsy with histological and immunohistochemical analyses confirmed SCC. Based on (1) a clear history of a primary tumor with a known metastatic propensity, (2) the absence of other primary sites on whole-body imaging, (3) histological features (highly consistent with the primary tumor type and no evidence of squamous metaplasia and dysplasia in the ductal or acinar epithelium), and (4) an immunohistochemical profile that effectively ruled out common primary parotid neoplasms, we retained solitary parotid metastasis as LSCC recurrence. However, definitive comparative molecular profiling, which is crucial for distinguishing recurrence from a second primary tumor, could not be performed because of resource limitations. Beyond the diagnostic challenge, this case highlights the complex intersection between rare metastatic sites and the risk of developing a secondary malignancy. In such scenarios, the decision to proceed with systemic therapy without definitive molecular proof of clonal relatedness depends on a robust convergence of clinical context, consistent imaging, and highly suggestive histopathological and immunohistochemical findings. It is imperative that traditional pathology and advanced molecular studies converge to provide not only a diagnosis but also a precise biological understanding of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.